Researchers at Mayo Clinic are studying regenerative medicine techniques for restoring tissue and organ function.

Active clinical trials include:

Clinical Trials

Filter by condition

13 studies in Center for Regenerative Medicine

  1. Zenith® TX2® Low Profile TAA Endovascular Graft Clinical Study

    Rochester, Minn. View Summary

    Zenith® TX2® Low Profile TAA Endovascular Graft Clinical Study

    Location:

    Rochester, Minn.

    Trial status:

    Open for Enrollment

    Why is this study being done?

    The Zenith® TX2® Low Profile TAA Endovascular Graft study is a clinical trial approved by US FDA to evaluate the safety and effectiveness of the Zenith® TX2® Low Profile TAA Endovascular Graft indicated for the treatment of patients with aneurysms/ulcers of the descending thoracic aorta having vessel structure suitable for repair.

    NCT ID:

    NCT01151020

    IRB Number:

    10-004191

    Who can I contact for additional information about this study?

  2. A Phase 1 Study of Autologous Mesenchymal Stromal Cell Coated Fistula Plug in Patients With Fistulizing Crohn s Disease.

    Rochester, Minn. View Summary

    A Phase 1 Study of Autologous Mesenchymal Stromal Cell Coated Fistula Plug in Patients With Fistulizing Crohn s Disease.

    Location:

    Rochester, Minn.

    Trial status:

    Open for Enrollment

    Why is this study being done?

    The investigators propose to study the safety of autologous mesenchymal stromal cell transfer using a biomatrix (the Gore® Bio-A®; Fistula Plug) in a Phase I study using a single dose of 20 million cells. Twenty adult patients (age 18 years or older) with refractory, complicated perianal fistulizing Crohn's disease will be enrolled. Subjects will undergo standard adjuvant therapy including drainage of infection and placement of a draining seton with continuation of pre-existing anti-Crohn's therapy. Six weeks post placement of the draining seton, the seton will be replaced with the MSC loaded Gore® Bio-A® fistula plug as per current clinical practice. The subjects will be subsequently followed for fistula response and closure for 24 months. This is an autologous product derived from the patient and used only for the same patient.

    NCT ID:

    NCT01915927

    IRB Number:

    12-009716

    Who can I contact for additional information about this study?

    Rochester: Gwen M Boe, RN 507-266-9917
                        


  3. Phase I Study of Autologous Mesenchymal Stem Cells in the Treatment of Atherosclerotic Renal Artery Stenosis

    Rochester, Minn. View Summary

    Phase I Study of Autologous Mesenchymal Stem Cells in the Treatment of Atherosclerotic Renal Artery Stenosis

    Location:

    Rochester, Minn.

    Trial status:

    Open for Enrollment

    Why is this study being done?

    Individuals with unilateral arterial occlusive disease will be treated to injured kidney with autologous cells.

    NCT ID:

    NCT01840540

    IRB Number:

    12-009298

    Who can I contact for additional information about this study?

  1. Prev
  2. 1
  3. 2